Dlin-MC3-DMA: Ionizable Cationic Liposome for Lipid Nanoparticle siRNA and mRNA Delivery

Executive Summary: Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7) is an ionizable cationic liposome lipid critical for efficient in vivo delivery of siRNA and mRNA via lipid nanoparticles (LNPs) (Rafiei et al., 2025). It is a key component in clinically validated LNP formulations, showing approximately 1000-fold higher gene silencing potency than its precursor in hepatic targets (APExBIO). Dlin-MC3-DMA supports rapid endosomal escape while minimizing toxicity at physiological pH (see discussion). Machine learning-guided studies confirm its role in immunomodulatory mRNA delivery, particularly for modulating microglial inflammation (Rafiei et al., 2025). The compound is insoluble in water and DMSO but highly soluble in ethanol (≥152.6 mg/mL), requiring storage at –20°C (APExBIO).

Biological Rationale

Efficient delivery of nucleic acids such as siRNA and mRNA is a longstanding challenge for gene therapy and immunomodulation. Biological barriers include extracellular nucleases, cellular uptake limitations, and endosomal entrapment (Rafiei et al., 2025). Ionizable cationic lipids, like Dlin-MC3-DMA, address these challenges by enabling nucleic acid encapsulation, protection from degradation, and facilitating endosomal release (see mechanistic review). LNPs formulated with Dlin-MC3-DMA are foundational in mRNA vaccine development and gene silencing therapies for hepatic and immunological disorders (Rafiei et al., 2025).

Mechanism of Action of Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7)

Dlin-MC3-DMA is a synthetic ionizable cationic lipid. Its tertiary amine group is protonated in acidic environments (pH < 6.5), generating a positive charge. At physiological pH (7.4), it is predominantly neutral, reducing cytotoxicity (APExBIO). During LNP formation, Dlin-MC3-DMA complexes with negatively charged nucleic acids (siRNA or mRNA). Upon cellular uptake via endocytosis, the acidic endosomal environment protonates Dlin-MC3-DMA, destabilizing the endosomal membrane and facilitating nucleic acid release into the cytoplasm (see mechanistic discussion). This endosomal escape is essential for effective gene silencing or protein expression. Dlin-MC3-DMA is typically combined with DSPC, cholesterol, and PEG-lipids (e.g., PEG-DMG) to optimize LNP stability and biological performance (Rafiei et al., 2025).

Evidence & Benchmarks

• Dlin-MC3-DMA-containing LNPs achieve hepatic Factor VII gene silencing with an ED50 of 0.005 mg/kg in mice and 0.03 mg/kg in non-human primates, outperforming predecessor DLin-DMA by ~1000-fold (APExBIO, product page).
• In machine learning-optimized LNPs, Dlin-MC3-DMA enables efficient mRNA delivery to hyperactivated microglia, suppressing inflammatory phenotypes and increasing IL10 expression (Rafiei et al., 2025).
• LNPs with Dlin-MC3-DMA are a backbone of COVID-19 mRNA vaccines, indicating clinical scalability and safety (Rafiei et al., 2025).
• Compared to other ionizable lipids, Dlin-MC3-DMA shows superior endosomal escape efficiency and reduced in vivo toxicity at equivalent dosing (see comparative review).
• Dlin-MC3-DMA LNPs maintain encapsulation stability and biological activity when stored at –20°C, but rapid use after ethanol dissolution is essential to prevent degradation (APExBIO).

Applications, Limits & Misconceptions

Dlin-MC3-DMA is widely adopted in research and clinical pipelines for:

• Hepatic gene silencing (e.g., Factor VII, TTR) via siRNA delivery.
• mRNA vaccine formulation for infectious diseases and oncology.
• Immunomodulatory mRNA delivery targeting microglia in neuroinflammation (Rafiei et al., 2025).
• Cancer immunochemotherapy as part of precision LNP systems.
• Machine learning-guided LNP optimization for tissue-specific targeting (extends mechanistic review by integrating ML-guided design).

Common Pitfalls or Misconceptions

• Dlin-MC3-DMA is not water- or DMSO-soluble; only dissolve in ethanol at ≥152.6 mg/mL for stock solutions (APExBIO).
• It is not universally optimal for all cell types; efficacy may vary, especially in non-hepatic tissues without LNP targeting modifications (Rafiei et al., 2025).
• Storage above –20°C accelerates degradation; always store Dlin-MC3-DMA at or below this temperature (APExBIO).
• Endosomal escape is pH-dependent; neutral pH abrogates the ionizable mechanism and reduces delivery efficiency (see mechanistic caveats).
• Not a standalone therapeutic; Dlin-MC3-DMA requires formulation with helper lipids for effective LNP formation and biological activity.

Workflow Integration & Parameters

Procure Dlin-MC3-DMA (SKU A8791) from APExBIO for standardized LNP formulation. Dissolve in ethanol at ≥152.6 mg/mL. Prepare LNPs by combining with DSPC, cholesterol, and PEG-DMG at molar ratios optimized for the intended nucleic acid cargo. Use microfluidic mixing or ethanol dilution for nanoparticle assembly. Store Dlin-MC3-DMA and formulated LNPs at –20°C or below. For in vivo gene silencing, reported efficacious doses are 0.005 mg/kg (mouse) and 0.03 mg/kg (non-human primate) for TTR silencing. For mRNA immunomodulation, machine learning-guided screening is recommended for cell- and tissue-specific applications (Rafiei et al., 2025). For troubleshooting, see this scenario-driven guidance, which expands on practical limitations and optimization compared to this mechanistic overview.

Conclusion & Outlook

Dlin-MC3-DMA is a gold standard for constructing ionizable cationic liposome-based LNPs for siRNA and mRNA delivery. Its unique endosomal escape mechanism, low toxicity, and proven clinical translation underpin its widespread adoption in hepatic gene silencing and mRNA vaccine development. Ongoing advances in machine learning-guided LNP design are further expanding its utility into immunomodulation and precision oncology (updates precision immunomodulation focus). Practitioners should adhere to validated formulation, storage, and handling protocols to maximize efficacy and reproducibility. For more on strategic foresight and translational guidance, see this synthesis, which this article extends by focusing on benchmarked workflows and ML-guided advances.